{"id":6707,"date":"2022-12-06T10:05:00","date_gmt":"2022-12-06T10:05:00","guid":{"rendered":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-startat-fas-1-studien-med-nex-20-enligt-plan\/"},"modified":"2022-12-06T10:05:00","modified_gmt":"2022-12-06T10:05:00","slug":"nanexa-har-startat-fas-1-studien-med-nex-20-enligt-plan","status":"publish","type":"mfn_news","link":"https:\/\/nanexa.com\/sv\/mfn_news\/nanexa-har-startat-fas-1-studien-med-nex-20-enligt-plan\/","title":{"rendered":"Nanexa har startat Fas 1-studien med NEX-20 enligt plan"},"content":{"rendered":"
\n

Nanexa AB (publ) meddelar idag att f\u00f6rsta dosen av NEX-20 har administrerats i Fas 1-studien NEX-20-01.<\/strong><\/p>\n<\/div>\n

\n

NEX-20-01 \u00e4r en Fas 1-studie d\u00e4r friska frivilliga f\u00e5r en singel-injektion av NEX-20 och sedan f\u00f6ljs med avseende p\u00e5 den farmakokinetiska profilen, s\u00e4kerhet och tolerabilitet av l\u00e4kemedlet. Studien \u00e4r designad att studera olika dosniv\u00e5er i sekventiella dosgrupper, baserat p\u00e5 utv\u00e4rdering av data under studiens g\u00e5ng.<\/p>\n

\u201dEfter att ha genomf\u00f6rt ett prekliniskt program f\u00f6r NEX-20 kommer vi med denna studie nu kunna bekr\u00e4fta hur l\u00e5ng dep\u00e5 vi har av v\u00e5r f\u00f6rsta PharmaShell\u00ae-beredning av lenalidomid i m\u00e4nniska. Dessa data fr\u00e5n friska frivilliga m\u00f6jligg\u00f6r v\u00e5r fortsatta planering f\u00f6r dosering av NEX-20 i patienter med den livshotande blodcancersjukdomen multipelt myelom. Detta \u00e4r ytterligare ett stort steg fram\u00e5t f\u00f6r Nanexa att med PharmaShell\u00ae minska behandlingsb\u00f6rdan f\u00f6r patienter och v\u00e5rdgivare \u201d, s\u00e4ger David Westberg, VD f\u00f6r Nanexa.<\/p>\n

NEX-20 \u00e4r en l\u00e5ngtidsverkande formulering av lenalidomid, baserad p\u00e5 Nanexas drug delivery-system PharmaShell\u00ae. Lenalidomid \u00e4r en immunmodulerande substans som verkar s\u00e5v\u00e4l p\u00e5 cancercellerna som p\u00e5 den omgivande mikromilj\u00f6n (1). Idag ges lenalidomid till patienter i form av en oral kapsel en g\u00e5ng om dagen under 21-28 dagar i str\u00e4ck i behandlingscykler om 28 dagar.<\/p>\n

Studier visar en bristf\u00e4llig efterlevnad avseende daglig peroral behandling med lenalidomid hos m\u00e5nga patienter med multipelt myelom (2). NEX-20 som ges p\u00e5 kliniken kommer att kunna ers\u00e4tta en daglig oral dos lenalidomid med en enda injektion per m\u00e5nad, vilket s\u00e4kerst\u00e4ller att patienter f\u00e5r sin r\u00e4tta dos under hela behandlingen. \u201dDen h\u00e4r typen av skr\u00e4ddarsydda dep\u00e5beredningar \u00e4r hoppingivande f\u00f6r patienter eftersom man kan f\u00f6rv\u00e4nta sig en b\u00e4ttre klinisk effekt som ett resultat av en f\u00f6rb\u00e4ttrad behandlingsefterlevnad\u201d, s\u00e4ger David Westberg.<\/p>\n

Referenser:<\/p>\n

    \n
  1. A review of the history, properties, and use of the immunomodulatory compound lenalidomide Zeldis et al. Ann N Y Acad Sci. 2011 Mar;1222:76-82<\/li>\n
  2. Adherence to Lenalidomide in Older Adults With Newly Diagnosed Multiple Myeloma. Hira Mian, Mark Fiala, Tanya M Wildes Clin Lymphoma Myeloma Leuk. 2020;20(2):98-104.e1. doi: 10.1016\/j.clml.2019.09.618. Epub 2019 Oct 9. PMID: 31843543<\/li>\n<\/ol>\n<\/div>\n
    \n

    F\u00f6r mer information kontakta:<\/strong><\/p>\n

    \n

    David Westberg \u2013 VD, Nanexa AB (publ)\u00a0
    Telefon: 0709-42 83 03
    E-post:\u00a0david.westberg@nanexa.se<\/a>
    www.nanexa.com<\/a><\/p>\n

    Erik Penser Bank \u00e4r bolagets Certified Adviser och n\u00e5s p\u00e5 08-463 83 00, e-post: certifiedadviser@penser.se<\/p>\n<\/div>\n

    \n

    Om Nanexa AB (publ)<\/strong><\/p>\n

    \n

    Nanexa \u00e4r ett l\u00e4kemedelsbolag som utvecklar injicerbara l\u00e4kemedel baserade p\u00e5 det patenterade och innovativa drug delivery-systemet PharmaShell\u00ae \u2013 ett system som m\u00f6jligg\u00f6r n\u00e4sta generations l\u00e5ngverkande injicerbara l\u00e4kemedel med h\u00f6g drug load, tillverkade med atomlagerprecision. Nanexa utvecklar egna produkter och har dessutom samarbetsavtal med flera l\u00e4kemedelsbolag, d\u00e4ribland AstraZeneca.<\/p>\n

    Nanexas aktie \u00e4r noterad p\u00e5 Nasdaq First North Growth Market i Stockholm (NANEXA).<\/p>\n<\/div>\n

    \n

    Bifogade filer<\/strong><\/p>\n

    \n

    Nanexa har startat Fas 1-studien med NEX-20 enligt plan<\/a><\/p>\n<\/div>\n","protected":false},"excerpt":{"rendered":"

    Nanexa AB (publ) meddelar idag att f\u00f6rsta dosen av NEX-20 har administrerats i Fas 1-studien NEX-20-01.<\/p>\n","protected":false},"template":"","class_list":["post-6707","mfn_news","type-mfn_news","status-publish","hentry","mfn-news-tag-mfn-ci_sv","mfn-news-tag-mfn-type-ir_sv","mfn-news-tag-mfn_sv","mfn-news-tag-mfn-ci-other_sv","mfn-news-tag-mfn-lang-sv_sv"],"acf":[],"yoast_head":"\nNanexa har startat Fas 1-studien med NEX-20 enligt plan - Nanexa AB<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/nanexa.com\/mfn_news\/nanexa-har-startat-fas-1-studien-med-nex-20-enligt-plan\/\" \/>\n<meta property=\"og:locale\" content=\"sv_SE\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Nanexa har startat Fas 1-studien med NEX-20 enligt plan - Nanexa AB\" \/>\n<meta property=\"og:description\" content=\"Nanexa AB (publ) meddelar idag att f\u00f6rsta dosen av NEX-20 har administrerats i Fas 1-studien NEX-20-01.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/nanexa.com\/mfn_news\/nanexa-har-startat-fas-1-studien-med-nex-20-enligt-plan\/\" \/>\n<meta property=\"og:site_name\" content=\"Nanexa AB\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Ber\u00e4knad l\u00e4stid\" \/>\n\t<meta name=\"twitter:data1\" content=\"2 minuter\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-har-startat-fas-1-studien-med-nex-20-enligt-plan\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-har-startat-fas-1-studien-med-nex-20-enligt-plan\\\/\",\"name\":\"Nanexa har startat Fas 1-studien med NEX-20 enligt plan - Nanexa AB\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\"},\"datePublished\":\"2022-12-06T10:05:00+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-har-startat-fas-1-studien-med-nex-20-enligt-plan\\\/#breadcrumb\"},\"inLanguage\":\"sv-SE\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-har-startat-fas-1-studien-med-nex-20-enligt-plan\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/nanexa-har-startat-fas-1-studien-med-nex-20-enligt-plan\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Hem\",\"item\":\"https:\\\/\\\/nanexa.com\\\/sv\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MFN News Items\",\"item\":\"https:\\\/\\\/nanexa.com\\\/mfn_news\\\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Nanexa har startat Fas 1-studien med NEX-20 enligt plan\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#website\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"name\":\"Nanexa AB\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/nanexa.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"sv-SE\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#organization\",\"name\":\"Nanexa AB\",\"url\":\"https:\\\/\\\/nanexa.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"sv-SE\",\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"contentUrl\":\"https:\\\/\\\/nanexa.com\\\/wp-content\\\/uploads\\\/2015\\\/04\\\/nanexa-logo.png\",\"width\":165,\"height\":50,\"caption\":\"Nanexa AB\"},\"image\":{\"@id\":\"https:\\\/\\\/nanexa.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Nanexa har startat Fas 1-studien med NEX-20 enligt plan - Nanexa AB","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-startat-fas-1-studien-med-nex-20-enligt-plan\/","og_locale":"sv_SE","og_type":"article","og_title":"Nanexa har startat Fas 1-studien med NEX-20 enligt plan - Nanexa AB","og_description":"Nanexa AB (publ) meddelar idag att f\u00f6rsta dosen av NEX-20 har administrerats i Fas 1-studien NEX-20-01.","og_url":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-startat-fas-1-studien-med-nex-20-enligt-plan\/","og_site_name":"Nanexa AB","twitter_card":"summary_large_image","twitter_misc":{"Ber\u00e4knad l\u00e4stid":"2 minuter"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-startat-fas-1-studien-med-nex-20-enligt-plan\/","url":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-startat-fas-1-studien-med-nex-20-enligt-plan\/","name":"Nanexa har startat Fas 1-studien med NEX-20 enligt plan - Nanexa AB","isPartOf":{"@id":"https:\/\/nanexa.com\/#website"},"datePublished":"2022-12-06T10:05:00+00:00","breadcrumb":{"@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-startat-fas-1-studien-med-nex-20-enligt-plan\/#breadcrumb"},"inLanguage":"sv-SE","potentialAction":[{"@type":"ReadAction","target":["https:\/\/nanexa.com\/mfn_news\/nanexa-har-startat-fas-1-studien-med-nex-20-enligt-plan\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/nanexa.com\/mfn_news\/nanexa-har-startat-fas-1-studien-med-nex-20-enligt-plan\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Hem","item":"https:\/\/nanexa.com\/sv\/"},{"@type":"ListItem","position":2,"name":"MFN News Items","item":"https:\/\/nanexa.com\/mfn_news\/"},{"@type":"ListItem","position":3,"name":"Nanexa har startat Fas 1-studien med NEX-20 enligt plan"}]},{"@type":"WebSite","@id":"https:\/\/nanexa.com\/#website","url":"https:\/\/nanexa.com\/","name":"Nanexa AB","description":"","publisher":{"@id":"https:\/\/nanexa.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/nanexa.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"sv-SE"},{"@type":"Organization","@id":"https:\/\/nanexa.com\/#organization","name":"Nanexa AB","url":"https:\/\/nanexa.com\/","logo":{"@type":"ImageObject","inLanguage":"sv-SE","@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/","url":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","contentUrl":"https:\/\/nanexa.com\/wp-content\/uploads\/2015\/04\/nanexa-logo.png","width":165,"height":50,"caption":"Nanexa AB"},"image":{"@id":"https:\/\/nanexa.com\/#\/schema\/logo\/image\/"}}]}},"_links":{"self":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news\/6707","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/mfn_news"}],"about":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/types\/mfn_news"}],"wp:attachment":[{"href":"https:\/\/nanexa.com\/sv\/wp-json\/wp\/v2\/media?parent=6707"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}